# Xenon Pharmaceuticals (XENE) — Analyst Forecast

XENE · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/xene/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 18 | 0 | 0 | 18 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $46.00 | $65.43 | $90.00 | 7 |

Last price $34.33 (as of Oct 15, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 6, 2026 | Guggenheim | Initiated Coverage | Buy | $73.00 |
| Sep 18, 2026 | Baird | Maintained | Outperform | $90.00 |
| Sep 18, 2026 | Needham | Maintained | Buy | $60.00 |
| Sep 18, 2026 | Deutsche Bank | Downgraded | Buy → Hold | $46.00 |
| Sep 18, 2026 | Wells Fargo | Maintained | Overweight | $64.00 |
| Sep 18, 2026 | Wedbush | Maintained | Outperform | $55.00 |
| Sep 18, 2026 | RBC Capital | Maintained | Outperform | $70.00 |
| Aug 7, 2026 | RBC Capital | Maintained | Outperform | $81.00 |
| May 27, 2026 | JP Morgan | Maintained | Overweight | $82.00 |
| May 12, 2026 | JP Morgan | Maintained | Overweight | $80.00 |
| May 8, 2026 | Needham | Maintained | Buy | $78.00 |
| May 8, 2026 | RBC Capital | Maintained | Outperform | $82.00 |
| Mar 16, 2026 | Wedbush | Maintained | Outperform | $63.00 |
| Mar 10, 2026 | HC Wainwright & Co. | Maintained | Buy | $74.00 |
| Mar 10, 2026 | Deutsche Bank | Maintained | Buy | $90.00 |
| Mar 10, 2026 | Wedbush | Maintained | Outperform | $64.00 |
| Mar 10, 2026 | Wells Fargo | Maintained | Overweight | $68.00 |
| Mar 9, 2026 | Baird | Maintained | Outperform | $97.00 |
| Mar 9, 2026 | Needham | Maintained | Buy | $80.00 |
| Feb 27, 2026 | Wells Fargo | Maintained | Overweight | $49.00 |

## Frequently Asked Questions

### What is the price target for XENE stock?

The average 12-month analyst price target for Xenon Pharmaceuticals (XENE) is $65.43, with a high estimate of $90.00 and a low of $46.00, across 7 analysts.

### Is XENE a buy, sell, or hold?

Analysts covering Xenon Pharmaceuticals currently average a Buy rating: 18 buy, 0 hold and 0 sell, from 18 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for XENE?

The average price target of $65.43 implies 90.59% upside from the last price of $34.33.

### What is the latest analyst rating on XENE?

On Oct 6, 2026, Guggenheim initiated coverage of Xenon Pharmaceuticals at Buy with a price target of $73.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).